Clinical Trials Browser

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Plasmacytoma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Clinical Trials

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

MagnetisMM-6

CARTITUDE-4

CARTITUDE-5

MajesTEC-3

MajesTEC-9

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

EXCALIBER-RRMM

ElLen

iMMagine-3

SUCCESSOR-1

CARTITUDE-6

CERVINO

MonumenTAL-6

DURGA-4

(COBRA)

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Perseus

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

DFCI 10-106

HO95

PrE1005

(Mel/MelVel)

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

FUMANBA-03

TT4B

DREAMM 8

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

DREAMM 7

DREAMM 7

Cassiopeia

DREAMM 8

VCAT

IMROZ

DREAMM 7

BOSTON

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Bellini

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

OPTIMISMM

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

KarMMa-3

ENDEAVOR